Analysts See $-0.72 EPS for Flex Pharma (FLKS), Zendesk (ZEN) SI Increased By 23.87%

July 13, 2017 - By Nellie Frank

Analysts expect Flex Pharma Inc (NASDAQ:FLKS) to report $-0.72 EPS on August, 2.They anticipate $0.01 EPS change or 1.41% from last quarter’s $-0.71 EPS. After having $-0.49 EPS previously, Flex Pharma Inc’s analysts see 46.94% EPS growth. About 14,908 shares traded. Flex Pharma Inc (NASDAQ:FLKS) has declined 70.24% since July 13, 2016 and is downtrending. It has underperformed by 86.94% the S&P500.

Zendesk Incorporated (NYSE:ZEN) had an increase of 23.87% in short interest. ZEN’s SI was 4.94M shares in July as released by FINRA. Its up 23.87% from 3.99 million shares previously. With 1.15M avg volume, 4 days are for Zendesk Incorporated (NYSE:ZEN)’s short sellers to cover ZEN’s short positions. About 122,960 shares traded. Zendesk Inc (NYSE:ZEN) has risen 6.73% since July 13, 2016 and is uptrending. It has underperformed by 9.97% the S&P500.

Among 14 analysts covering Zendesk (NYSE:ZEN), 13 have Buy rating, 0 Sell and 1 Hold. Therefore 93% are positive. Zendesk had 23 analyst reports since August 5, 2015 according to SRatingsIntel. The company was maintained on Wednesday, May 4 by Morgan Stanley. The firm earned “Overweight” rating on Thursday, July 14 by Morgan Stanley. The company was maintained on Wednesday, November 4 by Rosenblatt. The stock of Zendesk Inc (NYSE:ZEN) earned “Buy” rating by Guggenheim on Thursday, April 13. The rating was downgraded by Zacks to “Buy” on Wednesday, August 5. Guggenheim maintained Zendesk Inc (NYSE:ZEN) rating on Wednesday, April 19. Guggenheim has “Buy” rating and $33 target. On Thursday, September 10 the stock rating was initiated by William Blair with “Outperform”. The firm has “Outperform” rating given on Friday, September 11 by RBC Capital Markets. The firm has “Buy” rating by Goldman Sachs given on Tuesday, April 19. Credit Suisse upgraded the stock to “Outperform” rating in Friday, September 11 report.

Zendesk, Inc. is a software development company. The company has market cap of $2.74 billion. The Zendesk family of products is built to work together to help organizations understand and manage customer relationships. It currently has negative earnings. All Zendesk products share a common interface and are being developed to support a shared services infrastructure and common customer data platform.

Among 2 analysts covering Flex Pharma (NASDAQ:FLKS), 0 have Buy rating, 0 Sell and 2 Hold. Therefore 0 are positive. Flex Pharma had 3 analyst reports since August 21, 2015 according to SRatingsIntel. The company was upgraded on Wednesday, September 2 by Zacks. On Friday, August 21 the stock rating was downgraded by Zacks to “Hold”. The firm has “Hold” rating given on Friday, October 14 by Cantor Fitzgerald.

Flex Pharma, Inc. is a biotechnology company. The company has market cap of $61.86 million. The Firm develops treatments for nocturnal leg cramps, muscle cramps and spasms associated with severe neuromuscular conditions, and exercise associated muscle cramps . It currently has negative earnings. The Company’s product candidates activate certain receptors in primary sensory neurons, which then act through neuronal circuits to reduce the repetitive firing, or hyperexcitability, of alpha-motor neurons in the spinal cord, thereby preventing or reducing the frequency and intensity of muscle cramps and spasms.